US EditionHims launches $49 compounded copy of Wegovy weight-loss pill
Hims introduces a personalized oral semaglutide pill at $49 monthly, less than one-third of Novo Nordisk's $149 price, targeting patients avoiding injections amid rising GLP-1 demand.
- On Thursday, Hims & Hers announced it will offer a compounded oral semaglutide pill for $49 per month, undercutting Wegovy's $149 price and expanding from earlier injectables.
- Under U.S. compounding law, Section 503A allows small-scale personalized formulations; Hims says its copies are `personalized` and legal, using a different formulation that helps tailor treatment plans.
- Hims & Hers stock surged 10% after the announcement, while Novo dropped 7% and Lilly fell 6.1%, with Doustdar saying 170,000 people use the $149 starter dose.
- Novo Nordisk said all Wegovy doses are `in full supply` across the US and vowed legal and regulatory action, citing recent ADA Obesity Association guidance discouraging compounded GLP-1s due to safety concerns.
- Hims is racing to build market share before Lilly's rival arrives this year, following Novo's rollout of oral Wegovy filling around 50,000 prescriptions weekly and prior injectable compounded semaglutide sales in 2024.
104 Articles
104 Articles
Several months of infighting between Novo Nordisk and American Hims & Hers culminated yesterday.
Hims & Hers falls 8% after Novo's legal threat. Here's the latest
The stock of Hims and Hers dropped in premarket trading early Friday after a legal threat from Novo Nordisk. The online teleheath company announced on Thursday plans to launch a cheaper, copycat version of Novo's weight loss pill, prompting Novo to take legal action. Hims stock spiked as much ...
Roanoke Times
Hims & Hers to launch its copy of Wegovy pill
WASHINGTON — Telehealth company Hims & Hers said Thursday it will launch a cheaper, off-brand version of the weightloss pill Wegovy, just weeks after drugmaker Novo Nordisk launched its highly anticipated reformulation of the blockbuster medication.
Hims GLP-1 Weight Loss: What Consumers Should Know About the Reported $49 Compounded Semaglutide Pill, Novo Nordisk Response, and Telehealth Prescription Access in 2026 - Hims & Hers Health (NYSE:HIMS)
San Francisco, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Weight management concerns should be evaluated by a qualified
Novo Nordisk Threatens Legal Action After Hims & Hers Launches $49 Pill
On the same day that health and wellness supplement provider Hims & Hers Health, Inc. announced it would begin selling a compounded semaglutide pill for weight loss at $49 for the first month, Novo Nordisk on Feb. 5 said it would take legal and regulatory action against the company for infringement of its intellectual property. Novo Nordisk has manufactured its injectable drug Wegovy for weight loss since 2021 and announced on Jan. 5 that it wou…
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
